#Israel #Haifa #aMoon #Gastroenterology #MAGENTIQ EYE

MAGENTIQ EYE Secures Series A Investment from aMoon

MAGENTIQ EYE LTD., a prominent developer of artificial intelligence-based software for decision support in gastroenterology, has successfully completed a Series A funding round. This significant financial backing, spearheaded by aMoon, Israel's largest investment fund focusing on HealthTech, aims to propel the company's innovative AI capabilities and expand its commercial efforts in both the USA and Europe.

The funding will primarily support the commercialization of MAGENTIQ COLO™, an FDA and CE-approved solution that enhances the detection and analysis of polyps during colonoscopies, drastically increasing the identification rates of adenomas. With real-time insights, the system offers a comprehensive analysis of polyp categories and types, along with advanced AI-generated reports.

Joining aMoon in this investment round are notable internal investors such as Norgine Ventures BV from the Netherlands, Nina Capital from the EU and the USA, and Namarel Ventures SL from Spain. Additional private investors include Sake Bosch and Roon Doornink from the USA. As part of this investment, Roy Wiesner, a partner at aMoon, will join MAGENTIQ EYE’s board, bringing valuable strategic experience and a global perspective to the initiative.

Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE, expressed his enthusiasm regarding the partnership, stating, "This funding round marks an essential milestone for MAGENTIQ EYE. We're excited to welcome aMoon and Roy Wiesner on our journey. Their support will fast-track our innovation and market access, allowing us to meet the rising demand reflected in our robust pipeline of clinical studies and inquiries in the USA and Europe, making our advanced diagnostic tools accessible to more physicians and patients worldwide."

Wiesner noted, "We take pride in collaborating with MAGENTIQ EYE, a company at the forefront of AI-assisted colonoscopy. MAGENTIQ's solution is distinguished as the most precise on the market, offering the broadest functionality and cost-effective scalability for GI and laparoscopic applications. We are encouraged by the strong early commercial momentum and increasing interest from major strategic players seeking collaboration. This investment underscores aMoon's commitment to supporting transformative health technology solutions that can profoundly enhance patient treatment outcomes worldwide."

Currently, MAGENTIQ EYE is conducting clinical trials for diagnostic tools targeting specific conditions of the upper and lower gastrointestinal tract, including ulcerative colitis, early dysplasia of Barrett's esophagus, and gastric intestinal metaplasia. The proceeds from the funding round will further develop and expand these capabilities, fostering commercial growth in the US, Europe, and globally through direct sales and new partnerships with industry leaders.

About MAGENTIQ EYE Ltd.

Founded in 2014, MAGENTIQ EYE has developed a groundbreaking AI-based solution for colonoscopy that is recognized for delivering one of the best performances known today. The company is well-regarded within the gastroenterology community, conducting numerous procedures daily with the MAGENTIQ COLO™ system, which sets a new standard in colonoscopy and saves lives.

For more information, visit MAGENTIQ EYE.

About aMoon

aMoon is a global healthtech and life sciences venture capital fund based in Israel, managing $1.3 billion in assets. The fund collaborates with entrepreneurs who utilize groundbreaking science and technology to transform healthcare, helping individuals lead better and healthier lives. Supported by a team of scientists, doctors, and entrepreneurs, along with a global network of investors and industry leaders, aMoon connects portfolio companies with global technology, finance, and medical research centers. Their Velocity Fund invests from company inception to Series A, while their Growth Fund supports later-stage companies in growth, pre-IPO, or critical clinical rounds.